
LXEO Stock Forecast & Price Target
LXEO Analyst Ratings
Bulls say
Lexeo Therapeutics is a clinical-stage genetic medicine company with a pipeline of gene therapy candidates targeting cardiovascular diseases. The most advanced candidate, LX2006, is designed to deliver functional frataxin in patients with Friedreich's ataxia cardiomyopathy, while the next most advanced candidate, LX2020, is designed to deliver a functional PKP2 gene in arrhythmogenic cardiomyopathy patients. The company has a positive safety profile for systemic gene therapy and expects to engage with regulatory agencies in 2026 for its HEROIC program in PKP2-ACM. With forecasts for peak sales of $580.2 million in 2032 and $273.8 million in 2035 for LX2006 and LX2020, respectively, Lexeo's stock presents a promising investment opportunity.
Bears say
Lexeo Therapeutics is a clinical-stage genetic medicine company that is currently developing gene therapy treatments for cardiovascular diseases such as Friedreich's ataxia, cardiomyopathy, and arrhythmogenic cardiomyopathy. While the company's therapies have shown some promising efficacy signals, the data is still lacking in terms of showing a clear and consistent story. Furthermore, the company's programs face significant competition, and its current pipeline does not have a large market potential, leading to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LXEO Analyst Forecast & Price Prediction
Start investing in LXEO
Order type
Buy in
Order amount
Est. shares
0 shares